- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02844751
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
Safety and Effectiveness of Autologous Regenerative Cell Therapy on Pain and Inflammation Associated With Osteoarthritis of the Knee
Study Overview
Status
Conditions
Detailed Description
This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the knee. Follow-up will consist of a larger sample including 4,000 patients.
Patients will be treated for Osteoarthritis (OA) of the knee due to degeneration or chronic injury. They will be treated with autologous Stromed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints.
Cohort 1 will include PRP treatments at time of initial StroMed treatment plus at 1 week, 2 weeks and 1 month.
Cohort 2 will include PRP treatments at time of initial StroMed treatment plus at 1 month and 2 months.
Patient outcomes will be tracked with a follow up MRI at various endpoints to 6 months, laboratory tests for inflammation markers, and knee injury and osteoarthritis outcome score (KOOS) questionnaires. SF-36 forms (a quality of life measure) and numerical rating scales (NRS) will also be used to assess safety and efficacy of treatment, as well as any reduction in patient medication and/or delay in pending knee replacement therapy.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Michael P Hutchinson, DVM
- Phone Number: 412-503-3788
- Email: drmike@vivatechusa.com
Study Contact Backup
- Name: Scott M Herkes, MBA
- Phone Number: 855-984-8287
- Email: scott.herkes@gmail.com
Study Locations
-
-
Pennsylvania
-
Grove City, Pennsylvania, United States, 16127
- Recruiting
- VivaTech International, Inc.
-
Contact:
- Michael P Hutchinson, DVM
- Phone Number: 412-503-3788
- Email: drmike@vivatechusa.com
-
Principal Investigator:
- Mark LoDico, MD
-
Contact:
- Scott M Herkes, MBA
- Phone Number: 855-984-8287
- Email: scott.herkes@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with indication of Osteoarthritis, grade 2 or more. Can be from degeneration or chronic injury.
- Patients range from 18-90 years of age.
- Patients must be able to comply with treatment plan, laboratory tests and periodic interviews.
- Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl.
- Patients with adequate cardiac and respiratory function.
- Patients with adequate blood coagulation activity, PT(INR) < 1.5, APTT
- Patients must have adequate immune system function, with no known immunodeficiency disease.
- Greater than 6 months knee pain on the index side (left or right knee).
Exclusion Criteria:
- Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
- Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke).
- Diagnosis of a transient ischemic attack in the 6 months prior to screening.
- Patients infected with hepatitis B, C or HIV.
- Patients with Body Mass Index (BMI) > 40kg/m2
- Presence of active infection.
- Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study.
Conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to:
- Knee instability.
- A varus/valgus deformity of more than 10o, a deformity requiring osteotomy or complex surgery.
- Gout or pseudo gout
- Treatments with strong opioid drugs in the previous 4 weeks for other pain rather than knee osteoarthritis
- Corticosteroid injection at treatment site within 1 month
- Consistent use of NSAIDs within 48 hours of procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Interventions assigned by Principal Investigator
|
[Day 0] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix.
In addition, the cells have not been altered by manipulation with enzymes or culturing.
This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added.
Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
Days 7,14 and 30
Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
Days 30 and 60
|
Experimental: Cohort 2
Interventions assigned by Principal Investigator
|
[Day 0] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix.
In addition, the cells have not been altered by manipulation with enzymes or culturing.
This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added.
Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
Days 7,14 and 30
Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
Days 30 and 60
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change is being assessed for the KOOS survey (Knee Osteoarthritis Outcome Score)
Time Frame: 0, 2, 6 months
|
Knee osteoarthritis outcome score
|
0, 2, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change is being assessed by MRI of afflicted joint
Time Frame: 0 and (6 - 12 months optional)
|
Looking for cartilage regrowth via MRI
|
0 and (6 - 12 months optional)
|
Change is being assessed for the SF36 survey (Short Form Health Survey)
Time Frame: 0,2,6 months
|
Short Form health Survey
|
0,2,6 months
|
Change is being assessed for the NRS survey (Numerical Rating Scale for Pain)
Time Frame: 0,2,6 months
|
Numerical Rating Scale for pain
|
0,2,6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark LoDico, MD, Advanced Regenerative Medicine
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRCM-2016-112
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on [StroMed + platelet rich plasma (PRP)]
-
VivaTech International, Inc.RecruitingOsteoarthritisUnited States
-
VivaTech International, Inc.Recruiting
-
Stanford UniversityPartnership for Clean CompetitionCompletedRheumatic Diseases | TendinopathyUnited States
-
Damascus UniversityCompletedBone ResorptionSyrian Arab Republic
-
Sutherland Medical CenterActive, not recruitingRotator Cuff Tears | Rotator Cuff TendinosisPoland
-
University of Colorado, DenverTerumo BCTCompletedOsteochondritis DissecansUnited States
-
Germans Trias i Pujol HospitalCompletedEvaluation of the Efficacy of Platelet-rich Plasma (PRP) on Advanced Endoscopic Resection TechniquesEndoscopic Submucosal Dissection | Platelet-rich Plasma | Endoscopic Mucosal ResectionSpain
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause, Premature | Menopausal Syndrome | Premature Ovarian Failure | Ovarian Failure, Premature | Menopause Related ConditionsGreece
-
University of Kansas Medical CenterUnknownTympanic Membrane PerforationUnited States
-
Cairo UniversityFayoum UniversityTerminated